InsidersTradesSigma
Browse the full directors' dealings record of Foundation Medicine, Inc., a listed equity based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was disclosed on 6 January 2016 (Cession). Among the most active insiders: Kafka Steven J.. All data is accessible without an account.
Analysts rate Foundation Medicine, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
2 of 2 declarations
Foundation Medicine, Inc. is a company focused on developing genomic tests for cancer. It provides solutions that assist physicians in personalizing treatments for their patients.